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We present the case of a diabetic man who was successfully treated with ertapenem for over 4 months for severe infection of his
foot ulcers. After initial unsuccessful treatment with empirical intravenous antibiotics, ertapenem was started on microbiology
advice and led to a marked improvement in the soft-tissue infection. Ertapenem was continued for a total of 137 days under close
clinical and biochemical monitoring and produced a complete resolution of the foot infection. This is the ﬁrst documented case
that we know of in which ertapenem has been safely used for this duration of time.
1.Introduction
We present the case of a diabetic man who was successfully
treatedwithertapenemforover4monthsforsevereinfection
of his foot ulcers. This is the ﬁrst documented case that we
know of in which ertapenem has been safely used for this
duration of time.
2. Case Presentation
A 69-year-old Caucasian type 2 diabetic man presented to
theemergencydepartmentwitha2-monthhistoryofpainful
ulcers on his left foot which had been increasing in size. The
patient had been diagnosed with type 2 diabetes mellitus 13
years earlier. This was managed with metformin, gliclazide,
and rosiglitazone, although the patient admitted to not
having taken these medications for over a year. His medical
history included hypertension, hypercholesterolaemia, and a
previous myocardial infarction. He had a smoking history of
50 pack years, drank approximately 2 units of alcohol per
week, and was independent in all activities of daily living.
The patient was started on oral ﬂucloxacillin (500mgqds)
and metronidazole (400mgtds) and discharged from the
emergency department to be seen 4 days later in the diabetic
foot clinic.
In the clinic, the patient was found to be hypertensive
(blood pressure 164/88mmHg) and tachycardic (pulse 110
beats per minute) with a temperature of 36.4◦C and oxygen
saturations of 93% on room air. He weighed 64.9kg and
was 1.67m tall, giving a body mass index of 23.3kg/m2.
Inﬂammatory markers in the blood were raised (normal
ranges in brackets): white cell count 16.2 × 109/l (4.0−11.0),
neutrophils 12.4 × 109/l (2.0−7.5) and c-reactive protein
46mg/l (0−6.0). His glycated haemoglobin was noted to be
16.5% (4.1−6.5).
Two ulcers were identiﬁed on the left foot: one on the
lateral aspect of the heel, measuring 5 × 6cm and the
other on the dorsal aspect of the left hallux, measuring
2 × 2cm. Both ulcers were necrotic and sloughy and
the bone of the hallux was visible through the second
ulcer. Peripheral pulses were palpable bilaterally but there
was marked peripheral neuropathy of both feet. Systemic
examination was unremarkable.
Swab cultures were taken but only skin ﬂora was
isolated (the details of this ﬂora were not disclosed in the
microbiology report, however). A speciﬁc anaerobic culture
was not performed. Blood cultures were also sent, but no
bacterial growth was detected, unsurprising given that the
patient had already been commenced on oral antibiotics.
Radiograph of the left foot demonstrated loss of soft tissues2 Case Reports in Medicine
Table 1: Microorganisms that ertapenem has in vitro and clinical activity against.
Aerobic and facultative gram-positive
microorganisms
Aerobic and facultative gram-negative
microorganisms Anaerobic microorganisms
Staphylococcus aureus (methicillin
susceptible isolates only) Escherichia coli Bacteroides fragilis
Streptococcus agalactiae Haemophilus inﬂuenzae
(beta-lactamase negative isolates only) Bacteroides distasonis
Streptococcus pneumoniae (penicillin




Moraxella catarrhalis Clostridium clostridioforme




at the ulcer sites but did not show any clear evidence of
osteomyelitis. However neither bone scan nor computerised
tomography (CT) was performed to conﬁrm the absence of
osteomyelitis.
The patient was admitted to a medical ward and started
on empirical intravenous antibiotics: benzylpenicillin 1.2g
qds, ﬂucloxacillin 500mgqds, and metronidazole 500mg
tds. The ulcers were debrided and daily dressings were
applied. The patient also had a short course of maggot
therapy to remove the necrotic tissue from the ulcers.
Debrided tissue was regrettably not sent for culture as
debridement was performed in the podiatry department and
not on the ward under medical supervision.
12 days after commencing intravenous antibiotics, oral
sodium fusidate 500mgtds was also started. On the same
day, the patient was reviewed by a vascular surgeon with
ankle brachial pressure index (ABPI) analysis revealing
moderate arterial disease, worse in the left leg compared
to the right (ABPI 0.51 in the left leg and 0.56 in the
right leg) (ABPI reference ranges: 1.0−1.3 normal, 0.9-1.0
acceptable, 0.8-0.9 mild arterial disease, 0.5−0.8 moderate
arterialdisease,and<0.5severearterialdisease).Thevascular
opinion at this stage was that if the ulcers did not heal with
conservative measures then amputation would have to be
considered.
3 weeks after the introduction of intravenous antibiotics
the appearance of the foot ulcers had not improved. In
addition, it appeared that an area of cellulitis was spreading
from proximal to the ulcers to the rest of the foot. Blood
tests revealed that the patient’s white cell count had risen to
19.6 × 109/l and the c-reactive protein had risen to 164mg/l.
However, throughout this time, the patient was afebrile.
The microbiology department were consulted and advised
stopping thecurrentantibiotics andcommencingthepatient
on intravenous ertapenem 1god.
6 weeks after starting ertapenem, the appearance of the
left foot was improved. There was signiﬁcantly less slough at
the base of the ulcers, but the heel ulcer was still necrotic.
Blood tests revealed that the white cell count had fallen to
14.2 × 109/l and the c-reactive protein had fallen to 9mg/l.
The patient remained afebrile. The decision was made to
continue ertapenem therapy as it was felt that the soft-
tissue infection had not completely resolved and as bone
involvement could not be ruled out, further antimicrobial
treatment would be required.
After 3 months of being on ertapenem, the appearances
of the foot ulcers had improved further with the inﬂamma-
tory markers in the blood also falling (white cell count 12.9×
109/l,c-reactiveprotein6mg/l)andthepatient’stemperature
remaining normal. The patient was being seen in the foot
clinic onaweeklybasiswithdebridementoftheulcerstaking
place when appropriate. The microbiology department felt
thatertapenemshouldbecontinuedasnoadverseeﬀectshad
been encountered and that the soft-tissue infection required
further treatment.
After over 4 months on ertapenem the ulcers had almost
completely healed with necrotic tissue no longer visible. The
patient’s white cell count had fallen to 12.3 × 109/l and
the c-reactive protein was 6mg/l. He had remained afebrile
throughout all this time. The patient’s glycated haemoglobin
was rechecked and had come down to 5.9%.
Ertapenem was stopped after 4 months and 16 days
of therapy (137 days in total). The patient had remained
in hospital for the full duration of the ertapenem therapy
to ensure compliance with all medications, so that the
aﬀected limb was free from weight bearing to allow pressure
relief and to permit regular debridement of the ulcers. The
patient was discharged home 2 weeks after the cessation of
ertapenem. Vascular review before discharge documented
that amputation no longer had to be considered at present
but that the patient would require close followup in the
community and would at some point require vascular
intervention.
3. Discussion
Foot infections account for approximately 20% of hospital
admissions in diabetic patients and up to 25% of allCase Reports in Medicine 3
diabetics are expected to develop severe foot problems at
some point during their life [1]. Infection is usually a
consequence of foot ulcerations which typically result from
trauma to a neuropathic foot. Other major risk factors for
ulcer formation are structural foot deformity and peripheral
vascular disease.
Diabetic foot infections are generally more severe and
harder to treat than infections seen in nondiabetic patients.
This is due to a number of factors including impaired
microvascular circulation, neuropathy, anatomical alter-
ations and impaired immune capacity in diabetic patients.
Ertapenem, a long-acting, 1β- m e t h y lp a r e n t e r a lg r o u p1
carbapenem antibiotic with a broad antibacterial spectrum
was licensed for clinical practice in Europe and the USA in
2002 [2]. It has a once-daily dosing regimen and is generally
well tolerated [3]. Ertapenem is active against gram positive,
gramnegative,andanaerobicbacteria(Table 1)andhasbeen
shown to be eﬀective in skin/soft-tissue infections [4].
Infection of diabetic foot ulcers is usually caused by
aerobic gram positive cocci, most commonly staphylococcus
aureus, haemolytic staphylococci (especially group B), and
coagulase negative staphylococci. Although monomicrobial
infections may occur, it is common for these gram positive
cocci to be found along with gram negative bacilli and
obligate anaerobes [5, 6]. In this case, the patient did not
respond to the initial antibiotic regimen of intravenous ben-
zylpenicillin, ﬂucloxacillin, andmetronidazole. This regimen
lacks coverage for facultative gram negative rods, and so the
failure could have been due to the inadequate coverage for
these organisms.
In this case, the only microbiology isolated was reported
as “skin ﬂora”. A multicentre clinical trial on the bacteriology
of diabetic foot infections published in 2007 found staphylo-
coccus epidermidis in nearly 50% of the coagulase negative
staphylococci isolates [7]. Citron et al. comment that S.
epidermis, often dismissed as a commensal or contaminant,
is now increasingly being recognised as a true pathogen in
diabetic foot infections. Although the organism is innocuous
on intact human skin, it can cause severe infections after it
penetratesanatomicalbarrierspartlythroughtheproduction
of proteases, peptidases, bioﬁlms, and surface lipoproteins
that promote host tissue adherence [7].
Citron et al. go on to state that because specimens
from most patients have polymicrobial cultures, empirical
therapy should be relatively broad spectrum with either
ertapenem or piperacillin-tazobactem being an appropriate
empirical single agent (except for methicillin resistant S.
aureus infections) [7].
Ertapenem has a broad spectrum of action, but it does
not provide cover against most enterococcus or pseudomonas
species which are often found in diabetic foot infections.
This would seemingly put ertapenem at a disadvantage to
piperacillin-tazobactam, which does cover these commonly
occurring species. However, a large multicentre, double-
blinded, randomised clinical trial published in 2005 demon-
strated that in diabetic foot infections treatment with a
once daily dose of ertapenem produced equivalent clinical
outcomes to treatment with a four-time daily dose of
piperacillin-tazobactam [8].
The recommended duration of antibiotic therapy in
diabetic foot infections ranges from 1−4 weeks for soft-tissue
infection alone to >6 weeks for unresected osteomyelitis.
The manufacturers recommend use of ertapenem for 7−14
days in complicated skin infections without osteomyelitis
[9]. Ertapenem was used for a total of 137 days in this case,
where the presence of osteomyelitis could not be accurately
ruled out. Ertapenem was used for this duration of time as
at each stage of review, it was felt that although the foot
infection was improving further treatment was needed, and
as there were no adverse eﬀects this length of therapy was
deemed acceptable by both the microbiology department
and the admitting medical team.
Clearly, other factors had an important role to play
in the resolution of the diabetic foot infection detailed in
this case aside from the antimicrobial treatment. When
the patient was initially seen in the diabetic foot clinic,
he admitted to not taking his oral hypoglycaemic med-
ications for over one year. Whilst he was an inpatient,
these medications were restarted and subsequently led to an
improvement in glycaemic control. This is reﬂected in the
fall in glycated haemoglobin from 16.5% on admission to
5.9% on discharge. In addition, the patient was not weight
bearing on the aﬀected limb throughout the duration of his
treatment which would have helped the healing of the foot
ulcers through pressure relief. Also the patient’s ulcers were
regularly debrided allowing healthy tissue to emerge after
nonviable tissue had been resected.
Thiscasedemonstratesthesafeuseofertapenemforover
4monthsintreatinginfecteddiabeticfootulcers.Inourcase,
it was highly eﬀective in treating the patient’s infected ulcers
when empirical therapies had been unsuccessful. Ertapenem
has a once-daily dosing regimen and has shown equivalent
results in the treatment of diabetic soft tissue infections to
themorewidelyuseddrugpiperacillin-tazobactem.Thiscase
highlights the fact that ertapenem could have a role as a ﬁrst
line intravenous antibiotic in the treatment of diabetic foot
infections and be used for long durations when required.
The once-daily dosing regimen of ertapenem also makes it a
suitable agent for prolonged outpatient or home intravenous
antibiotic therapy.
Consent
The patient described in the case has given informed consent
for the report to be published.
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